- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00973492
Impact of Functional Insulinotherapy on Blood Glucose Variability Indicators in Patients With Type 1 Diabetes (VARIAFIT)
The primary objective of this trial is to assess whether functional insulinotherapy decreases blood glucose variability at 3 months and 6 months, compared to initial values in type 1 diabetes patients.
So, this study measures the impact of functional insulinotherapy on several blood glucose variability indicators in patients with type 1 diabetes.
This trial also has a secondary objective: to measure the effect of functional insulinotherapy on oxidative stress and inflammation.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a prospective, open, non-controlled study with an individual benefit for the participant. This study is designed to assess whether functional insulinotherapy decreases blood glucose variability at 3 months and 6 months, compared to initial values in type 1 diabetes patients.
All 30 patients with type 1 diabetes attended a 4-day functional insulinotherapy class, taught by 2 nurses, 2 dieticians and 2 physicians. The participants were recruited among metabolically stable patients who had already been prescribed functional insulinotherapy.
To assess the impact of functional insulinotherapy on blood glucose variability, HbA1c will be measured at 0, 3 months and 6 months along with 4 blood glucose variability indicators: MAGE, ADRR, LI and LBGI.
This trial also has a secondary objective: to measure the effect of functional insulinotherapy on oxidative stress. Therefore, a measure of insulin antibodies by ELISA at baseline. At baseline and 6 months, LTE4, TXB2, 8-iso-PGF2alpha, anti-transglutaminase and anti-endomysium antibodies will also be assessed.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Grenoble Cedex 9, Frankrike, 38043
- Service de Diabétologie du Pr Halimi, CHU
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Patients with type 1 diabetes with pump or multi-injection treatment and attending a functional insulinotherapy class
- Social Security membership or benefit from Social Security
- Informed consent, with a signed and approved form
Exclusion Criteria:
- Underage patient, major patient under guardianship or protected by the Law
- Pregnant, parturient or breastfeeding woman
- Person with no freedom (prisoner), person in an emergency situation, person hospitalized without consent and not protected by the Law
- Antecedents of pathologies causing diabetes instability (coeliac disease, gastroparesis, non-balanced psychiatric pathology) and not optimally treated, acute pathology less than 3 months ago (infectious, cardio-vascular, metabolic), pregnancy
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
---|---|
patients with functional insulinotherapy
There is only one group in this study.
The participants will attend a functional insulinotherapy class.
|
The functional insulinotherapy class lasts for 4 days. It is taught by 2 nurses, 2 dieticians and 2 physicians to 6 to 10 patients. On day 1, patients describe their difficulties with diabetes. Fast-acting insulin scales are elaborated from preprandial and postprandial blood glucose levels. At dinner, patients start a 24-hour glucose-fasting period to evaluate their need for basal insulin. Meals contain virtually no carbohydrates. Correcting doses of insulin are administered if preprandial glycemia is over 1.50 g/l or postprandial glycemia is over 2 g/l. Blood glucose levels must stay within normal values during the whole 24-hour period. Carbohydrate management is taught during meals and every afternoon through workshops about dietetics. Patients also learn how to deal with hypoglycaemia, hyperglycaemia and physical activity. A one-day follow-up takes place 3 months later. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
MAGE, ADRR, Lability Index and LBGI computed with the blood glucose measurement or CGMS
Tidsramme: 0, 3 months, 6 months
|
0, 3 months, 6 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
anti-transglutaminase and anti-endomysium antibodies
Tidsramme: 0 months, 6 months
|
0 months, 6 months
|
dosage of urinary leucotriene E4 and 11-dehydro-thromboxane B2, 8-iso-PGF2alpha
Tidsramme: 0 months, 6 months
|
0 months, 6 months
|
anti-insulin antibodies by ELISA
Tidsramme: 0 months
|
0 months
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Pierre-Yves Benhamou, PhD, University Hospital, Grenoble
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2007-A00903-50
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Type 1 diabetes
-
Oxford Brookes UniversityUniversity of OxfordFullførtFysisk aktivitet | Mental helse velvære 1 | Kognitiv funksjon 1, sosial | Academic Attainment | Fitness TestingStorbritannia
-
IpsenAvsluttet
-
Merck Sharp & Dohme LLCRekrutteringIkke-småcellet lungekreft | Solide svulster | Programmert celledød-1 (PD1, PD-1) | Programmert celledød 1 ligand 1 (PDL1, PD-L1) | Programmert celledød 1 ligand 2 (PDL2, PD-L2)Japan
-
Rambam Health Care CampusIsrael Science FoundationFullført
-
Alvotech Swiss AGFullført
-
PfizerFullført
-
Stony Brook UniversityFullført
-
SanionaFullført
-
Calliditas Therapeutics ABEurofins Optimed; York Bioanalytical SolutionFullført
-
Calliditas Therapeutics ABFullført
Kliniske studier på functional insulinotherapy class
-
Mansoura UniversityFullført
-
Rutgers, The State University of New JerseyRekruttering
-
University of Wisconsin, MadisonUrban League of Greater Madison; African American Council of Churches Madison og andre samarbeidspartnereFullførtTro og fellesskap i handling: Økende bevissthet og håndtering av depresjon i afroamerikanske samfunnDepresjon | Selvledelse | BevissthetForente stater
-
Asir John SamuelMaharishi Markendeswar University (Deemed to be University)RekrutteringAkutt koronarsyndromIndia
-
Medical Research CouncilUkjentSelvskadende oppførselStorbritannia
-
VA Office of Research and DevelopmentFullført
-
University of Wisconsin, MadisonNational Institute on Minority Health and Health Disparities (NIMHD)Fullført
-
Recep Tayyip Erdogan University Training and Research...FullførtMuskelstyrke | Idrettsskade | MuskelkontraksjonTyrkia
-
Milton S. Hershey Medical CenterRekrutteringMobilitetsbegrensning | Gå, vanskelighetsgradForente stater
-
IRCCS Eugenio MedeaRekrutteringFor tidlig fødsel | Foreldre-barn forholdItalia